Clinical Trial Update: Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update evaluating tARlatamab for refractory advanced digestive neuroendocrine carcinomas. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma of Unknown Primary Origin
• Neuroendocrine Carcinoma of the Digestive System

Drugs mentioned

• Tarlatamab

Snippet

Sponsor: Grupo Espanol de Tumores Neuroendocrinos | Conditions: Advanced Neuroendocrine Carcinomas of The Digestive System, Advanced Neuroendocrine Carcinomas Unknown Primary Origin | Phase 2 | Status: RECRUITING